{"id":611961,"date":"2024-06-11T18:47:36","date_gmt":"2024-06-11T22:47:36","guid":{"rendered":"https:\/\/platohealth.ai\/adcytherix-emergence-team-reunites-for-another-adc-company\/"},"modified":"2024-06-12T05:48:10","modified_gmt":"2024-06-12T09:48:10","slug":"adcytherix-emergence-team-reunites-for-another-adc-company","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/adcytherix-emergence-team-reunites-for-another-adc-company\/","title":{"rendered":"Adcytherix: Emergence team reunites for another ADC company","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Emerging Company Profile<\/p>\n

\n
\n
\n

French biotech to pursue novel targets with ADCs incorporating new and old payloads<\/h2>\n

\n By Richard Guy, Biopharma Analyst<\/span>\n<\/p>\n

June 11, 2024 10:47 PM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

The management team behind Emergence Therapeutics is teaming up to launch a second ADC company, Adcytherix, less than a year after the acquisition of its first. This time, the focus isn\u2019t on developing a new ADC platform, but on case-by-case optimization of payloads and targets.<\/p>\n

Jack Elands, Xavier Preville and Carsten Dehning, Emergence co-founders and CFO, respectively, began working on Adcytherix S.A.S. with Pontifax Venture Capital just months after Emergence was acquired by Eli Lilly and Co. (NYSE:LLY) last year…<\/p>\n